-+ 0.00%
-+ 0.00%
-+ 0.00%

Altria Group (MO) Stock Contrasts Q3 Earnings Strength With Margin Squeeze

Simply Wall St·10/30/2026 23:43:25
Listen to the news

Altria Group just posted Q3 2026 numbers, and the stock barely flinched, up about 1.6% to US$78. It was a calm move for a business whose profit engine is doing more than coasting. Adjusted earnings per share reached US$1.51 and net income from ongoing operations came in at US$2.5b, underscoring how much cash this cigarette heavyweight still throws off.

The real story today is margin pressure meeting income hunger. Traders saw a steady high dividend and shrugged. Long term holders now have to decide whether a rich payout and raised full year guidance outweigh the squeeze in profitability that has been building underneath.

Love Altria Group's rich dividend stream but concerned about the margin squeeze in these earnings, especially if you rely on this kind of cash generator for income? You can help balance that trade off by comparing MO against our 5 dividend fortresses

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$6,132m vs. US$5,251m (up about 16.8%)
  • Net Income from Ongoing Operations (Q3 2026 vs. Q3 2025): US$2,518m vs. US$2,369m (up about 6.3%)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$1.51 vs. US$1.41 (up about 7.1%)
  • Trailing 12 Month Net Profit Margin (Q3 2026 vs. Q3 2025): 35.7% vs. 43.9% (margin compressed by about 8.2 percentage points)

Altria raised 2026 EPS guidance after a strong first 9 months. Ask Charlie what Altria’s higher 2026 EPS guide really assumes.

NYSE:MO Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
NYSE:MO Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

Evaluating Altria’s Smoke Free Transition Milestones

The bullish script on Altria Group hinges on smoke free progress showing up in hard numbers, not just slideware.

"The main factor that has to go right is that Altria Group continues to grow compliant smoke free products like on! PLUS fast enough, and with enough regulatory clarity, to offset cigarette volume declines and pressure in moist smokeless tobacco."

on! shipments grew 13.3% in Q3 to 47.8m cans and the pouch line now benefits from broader FDA marketing authorizations and a national on! PLUS rollout into higher nicotine SKUs. That is concrete movement toward the goal. Yet oral adjusted operating income declined 3.7% as moist smokeless weakness and heavier on! PLUS investment still cap the profit handoff from combustibles.

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there.

Altria smoke free promise still trails profit reality

The bearish worry is that Altria leans on cigarettes while oral tobacco fails to pull its weight.

"Although Altria Group is expanding on! PLUS distribution and securing additional FDA marketing approvals for nicotine pouches, the oral tobacco products segment adjusted OCI fell 8% in Q2 2026 and 4.2% in the first half. This points to ongoing pressure from higher investments and weaker moist smokeless volumes that could keep segment margins and earnings below what many investors expect."

Q3 does not break that pattern. on! cans shipped rose 13.3%, yet oral adjusted operating income still declined 3.7% with margin compression at the group level. Smokeable OCI and EPS guidance moved up, so Altria again relies on combustibles to cover a profit gap smoke free products have not yet closed.

Hunt Quiet Disconnects In Plain Sight

Altria Group just showed how a rich income stream can coexist with real margin strain under the surface. The real opportunity is finding stocks that could be undervalued before the market corrects them.

  • Company 1 - 34% below our estimate - turn long term optical and solar supply agreements and photonics demand into higher margin manufacturing utilization.
  • Company 2 - 48% below our estimate - convert a data center heavy project backlog into modular builds that keep mechanical and electrical crews booked.
  • Company 3 - 38% below our estimate - turn rising mainstream demand for coconut based drinks into scaled branded and private label volumes across retail and foodservice.

Those are three of them. See every one of the 29 undervalued companies on it →